Analysts Cut enGene After LEGEND Data Shows Unexpected Drop in Response Rates
enGene Therapeutics has seen at least five Wall Street firms reduce their ratings after interim results from the pivotal LEGEND trial for detalimogene in BCG-unresponsive high-risk non-muscle invasive bladder cancer revealed an unexplained fall in efficacy. The anytime complete response rate slipped to 54% from 63%, with the deterioration concentra…